234 related articles for article (PubMed ID: 34843071)
1. Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment.
Wen N; Zhao N; Xu H; Zhao Y; Ma J
Ir J Med Sci; 2022 Oct; 191(5):2105-2111. PubMed ID: 34843071
[TBL] [Abstract][Full Text] [Related]
2. Inter-alpha-trypsin inhibitor heavy chain 4: A serologic marker relating to disease risk, activity, and treatment outcomes of rheumatoid arthritis.
He K; He S; Su M
J Clin Lab Anal; 2022 Mar; 36(3):e24231. PubMed ID: 35064701
[TBL] [Abstract][Full Text] [Related]
3. Serum interα-trypsin inhibitor heavy chain H4 may be an anti-inflammatory marker reflecting disease risk, activity and treatment outcome of ankylosing spondylitis.
Sun Z; Zhang Y; Zhou H; Li J; Zhou Y; Wang L
Scand J Clin Lab Invest; 2023 Dec; 83(8):540-547. PubMed ID: 38156824
[TBL] [Abstract][Full Text] [Related]
4. Potential role of MALT1 as a candidate biomarker of disease surveillance and treatment response prediction in inflammatory bowel disease patients.
Wu Z; Bi Y
J Clin Lab Anal; 2022 Feb; 36(2):e24130. PubMed ID: 34997981
[TBL] [Abstract][Full Text] [Related]
5. JNK pathway-associated phosphatase illustrates low expression and negative correlations with inflammation, disease activity, and T-helper 17 cells in inflammatory bowel disease children.
Wang C; Bai C; Mao C; Leng X; Wang F; Guo X
J Clin Lab Anal; 2022 Sep; 36(9):e24488. PubMed ID: 35908771
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal change of serum inter-alpha-trypsin inhibitor heavy chain H4, and its correlation with inflammation, multiorgan injury, and death risk in sepsis.
Zhao X; Guo Y; Li L; Li Y
J Clin Lab Anal; 2023 Feb; 37(3):e24834. PubMed ID: 36725250
[TBL] [Abstract][Full Text] [Related]
7. Level of interleukin 17 in inflammatory bowel disease and its relation with disease activity.
Menesy A; Hammad M; Aref S; Abozeid FAM
BMC Gastroenterol; 2024 Apr; 24(1):135. PubMed ID: 38622545
[TBL] [Abstract][Full Text] [Related]
8. Increased circulating circular RNA_103516 is a novel biomarker for inflammatory bowel disease in adult patients.
Ye YL; Yin J; Hu T; Zhang LP; Wu LY; Pang Z
World J Gastroenterol; 2019 Nov; 25(41):6273-6288. PubMed ID: 31749597
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal Change of Serum Inter-α-Trypsin Inhibitor Heavy Chain H4 and its Relation with Inflammation, Disease Recurrence, and Mortality in Acute Ischemic Stroke Patients.
Zhang J; Hu J; Zhao W
Tohoku J Exp Med; 2023 Feb; 259(3):221-227. PubMed ID: 36596502
[TBL] [Abstract][Full Text] [Related]
10. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
Goll R; Moe ØK; Johnsen KM; Meyer R; Friestad J; Gundersen MD; Kileng H; Johnsen K; Florholmen JR
BMC Gastroenterol; 2022 Nov; 22(1):464. PubMed ID: 36384462
[TBL] [Abstract][Full Text] [Related]
12. CD99 refers to the activity of inflammatory bowel disease.
Zhou G; Yang W; Yu L; Yu T; Liu Z
Scand J Gastroenterol; 2017 Mar; 52(3):359-364. PubMed ID: 27866429
[TBL] [Abstract][Full Text] [Related]
13. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
[TBL] [Abstract][Full Text] [Related]
14. Leucine-Rich Alpha-2 Glycoprotein in Monitoring Disease Activity and Intestinal Stenosis in Inflammatory Bowel Disease.
Yoshida T; Shimodaira Y; Fukuda S; Watanabe N; Koizumi S; Matsuhashi T; Onochi K; Iijima K
Tohoku J Exp Med; 2022 Jul; 257(4):301-308. PubMed ID: 35598974
[TBL] [Abstract][Full Text] [Related]
15. Study of tumor necrosis factor receptor in the inflammatory bowel disease.
Souza RF; Caetano MAF; Magalhães HIR; Castelucci P
World J Gastroenterol; 2023 May; 29(18):2733-2746. PubMed ID: 37274062
[TBL] [Abstract][Full Text] [Related]
16. Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study.
Balderramo D; Yamamoto-Furusho J; Ponce de León E; de María J; Zubiaurre I; Pedreira S; Lis C; Brion L; de Paula JA
Gastroenterol Hepatol; 2024 Jan; 47(1):51-62. PubMed ID: 37062500
[TBL] [Abstract][Full Text] [Related]
17. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome.
Raddatz D; Bockemühl M; Ramadori G
Eur J Gastroenterol Hepatol; 2005 May; 17(5):547-57. PubMed ID: 15827446
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of C1q/TNF-related protein-3 in inflammatory bowel disease patients and its inverse association with inflammatory cytokines and insulin resistance.
Mohamadinarab M; Ahmadi R; Gholamrezayi A; Rahvar F; Naghdalipour M; Setayesh L; Moradi N; Fadaei R; Chamani E; Tavakoli T; Esteghamati A
IUBMB Life; 2020 Aug; 72(8):1698-1704. PubMed ID: 32311832
[TBL] [Abstract][Full Text] [Related]
19. Serum Interleukin-33 level in Saudi children with inflammatory bowel disease.
Saadah OI; Al-Harthi SE; Al-Mughales JA; Bin-Taleb YY; Baeshen RS
Int J Clin Exp Pathol; 2015; 8(12):16000-6. PubMed ID: 26884875
[TBL] [Abstract][Full Text] [Related]
20. [Could the cytokines concentration be a marker of IBD activity and be useful in evaluation of IBD differentiation?].
Cieċko-Michalska I; Wierzbicka-Tutka I; Szczepanek M; Fedak D; Mach T
Przegl Lek; 2016; 73(5):301-4. PubMed ID: 29629745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
